Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?
- 1 March 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 8 (5), 272-279
- https://doi.org/10.1038/nrclinonc.2011.19
Abstract
Adjuvant chemotherapy reduces the risk of relapse and mortality for women with early-stage breast cancer. However, many women diagnosed with early-stage breast cancer experience the toxic effects associated with adjuvant chemotherapy without any meaningful benefit. There are a variety of clinicopathological factors--including hormone receptor expression, histology, and proliferation markers such as Ki-67--that can be used to try to identify patients who can safely avoid adjuvant chemotherapy. In addition, novel molecular tools, including the intrinsic molecular subtypes, prognostic multigene assays, and levels of urokinase-type plasminogen activator, provide further prognostic and predictive information to the standard clinicopathological factors thereby improving the accuracy of risk-of-relapse estimation and of the likelihood of response to cytotoxic chemotherapy.Keywords
This publication has 87 references indexed in Scilit:
- Estimates of cancer incidence and mortality in Europe in 2008European Journal of Cancer, 2010
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialThe Lancet Oncology, 2010
- Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy responseBreast Cancer Research and Treatment, 2009
- The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancerBreast Cancer Research and Treatment, 2009
- Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapyBreast Cancer Research and Treatment, 2008
- Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast CancerJama-Journal Of The American Medical Association, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998